
GTXI
Other · Other · $4.1M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Mar 31, 2019
EPS trend, 90 days to now · 30-day revisions 0 up, 0 down
Beat estimates in 1 of the last 3 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 15, 2018 | Time not confirmed | -0.30 | -0.39 | -30.0% |
| Aug 14, 2018 | Time not confirmed | -0.43 | -0.43 | 0.0% |
| Mar 12, 2018 | Time not confirmed | -0.48 | -0.43 | +10.4% |
GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. It develops selective androgen receptor modulators (SARMs) for the treatment of breast cancer, SUI, and Duchenne muscular dystrophy; and selective androgen receptor degraders to treat progressive castration-resistant prostate…